Analyst Ratings for Summit Therapeutics plc (SMMT)
SMMT Rating Summary
SMMT Price Target Summary
- Highest: $40.00 (Citizens)
- Lowest: $9.80 (Bernstein SocGen Group)
- Average: $28.62
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$28.62 (+109.5%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
Avg. $ Target:
$28.62 (+109.5%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/22/2026 | H.C. Wainwright » Updated 7/23/2026 |
Mitchell S. Kapoor | Downgrade | Neutral (Buy) |
N/A (N/A) |
17.47 (13.66) |
-21.81% | Details |
| 5/21/2026 | Bernstein SocGen Group » Updated 6/22/2026 |
Jeffrey Walch | New Coverage | Underperform (N/A) |
9.80 (7.70) |
17.89 (13.66) |
-23.64% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
